Mild COVID-19 outpatients managed by General Practitioners in Northern Italy (Lombardy)

Mild, moderate and severe inpatients managed in different Italian Hospitals, mostly in Northern Italy (Lombardy)

COVID-19

Cardiovascular Risk Factor

Istituto Auxologico Italiano

Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up

Cardiovascular Risk in COVID-19 Patients: Metabolic, Prothrombotic and Proinflammatory Mechaninsms Associated With Outcome and With Cardiorespiratory Features During the Acute Viral Disease and at Short Term Follow-up

To obtain a multivariable model based on anthropometric, clinical and therapeutic variables that will allow to predict the development of severe COVID-19 and its complications

To Identify the role of selected clinical, pathophysiological and molecular mechanisms in the development of COVID-19 disease and its clinical manifestations of different severity

To Identify the clinical, immunological, inflammatory, viral, cardiorespiratory consequences of COVD-19 that may persist a few months after discharge and may affect mid- and long-term prognosis

Sharing individual participants data that underlie the results included in published articles, after deidentification

COVID

GastroMuñoz

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador

Clinical Characteristics of Patients With SARS-CoV-2 (COVID-19) Infection in Guayaquil, Ecuador: COVID-EC Study

To know the clinical characteristics of patients with COVID-19 treated in hospitals in Guayaquil, Ecuador.

Establish the prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death.

To determine the clinical characteristics of the patients with the worst prognosis.

Relate, at least retrospectively, the relationship that may exist between the different treatments and the prognosis.

Jorge Carriel M.

Physician

Hospital San Carlos, Madrid

Universidad Catolica Santiago de Guayaquil

Standard of care as directed by the treating clinicians, plus sarilumab 400 mg subcutaneous injection. Sarilumab is provided in prefilled syringes/pens containing 200 mg each as is used clinically, and both injections will be given as soon as is convenient after the patient has decided to enroll.

Standard of care as directed by the treating clinicians.

Single dose of 400 mg subcutaneous sarilumab

SARILUMAB

VA Connecticut Healthcare System

VA Boston Healthcare System

VA Medical Center - White River Junction

Sarilumab for Patients With Moderate COVID-19 Disease

Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design

Digital data underlying primary scientific publications will be held as part of a data sharing resource. Study data held for this purpose may include data, data content, format, and organization. The data may contain but are not limited to individually identifiable information, other PHI, and study codes. The data may be available to the public and other VA and non-VA researchers under certain conditions and consistent with the informed consent and CSP policy that prioritize protecting participants' privacy and confidentiality to the fullest extent possible. A detailed plan will be developed in accordance with current technology, infrastructure, best practices, and policies and procedures in place at the time of oversight committee reviews (e.g., Privacy Board, Information Security, and Information Technology standards). The plan will include how data will be discovered, retrieved, analyzed, and managed and will note the materials that are available in machine-readable formats.

Westyn Branch-Elliman

Assistant Professor of Medicine, Harvard Medical School; Investigator, VA Boston Center for Healthcare Organization and Implementation Research; Infectious Disease Consultant, VA Boston Healthcare System

Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.

Endstage Renal Disease

Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.

Sodium Propionate

Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis

Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study

endotoxin /lipopolysaccharide levels, high sensitivity C-reactive protein (hs-CRP), fibrinogen, interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), IL-10, IL-2, INFγ, TGFβ, IL-4, IL-1β, IL-17a and white blood cell count.

glutathione peroxidase, malone dialdehyde

Determination of Homa Index (Homeostasis Model Assessment) by measurement fasting blood sugar and insulin level as well as hemoglobin HbA1c. IR appears to be as associated of metabolic disorders including lipid abnormalities, atherosclerotic cardiovascular disease and accelerated muscle protein degradation (Wang et al. 2006). IL is induced in particular by systemic inflammation.

lymphopenia/obesità

Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador

Sarilumab for Patients With Moderate COVID-19 Disease

Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis

Il database di erbe medicinali più completo supportato dalla scienza